Clinical Trial Update: TIL and Anti-PD1 in Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tumor-infiltrating lymphocytes (TIL) and anti-PD1 therapy in metastatic melanoma; current status unknown with toxicity and adverse dr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-PD1
• TIL

Snippet

Sponsor: Leiden University | Conditions: Toxicity, Drug, Adverse Drug Event | Phase 1, Phase 2 | Status: UNKNOWN